Prior to joining Terremoto, Ron served as Vice President of Clinical Development at Mirati Therapeutics, where he led multiple clinical programs and cross-functional development efforts including MRTX1719 (MTA-cooperative PRMT5 inhibitor), MRTX0902 (SOS1 inhibitor), and sitravatinib (tyrosine kinase inhibitor). He also led collaboration efforts for adagrasib (KRAZATI®, KRAS^G12C selective inhibitor).

Prior to Mirati, Ron held senior leadership positions at several biotech companies including Denovo Biopharma, Inspyr Therapeutics, and TRACON Pharmaceuticals, where he was responsible for clinical strategy, regulatory affairs, global trial execution, and business development support. Earlier in his career, he held leadership roles at Pfizer and Bristol-Myers Squibb, where he oversaw clinical development programs in oncology, including early- and late-stage studies, and led interactions with global health authorities. He also served as a clinical lead for the elotuzumab (EMPLICITI™) registrational Phase 3 program in multiple myeloma.

Ron held academic appointments at UC San Diego, UCLA, and Cedars-Sinai Medical Center where he served as Director of Clinical Research at the Prostate Cancer Center.

Ron earned his M.D. from New York Medical College, his M.B.A. from the Anderson School of Management at UCLA, and his B.A. in Economics from the University of California, San Diego.